BioTelemetry, Inc. (BEAT - Free Report) is a manufacturer of cardiac monitoring devices that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BEAT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that BioTelemetry could be a solid choice for investors.
Current Quarter Estimates for BEAT
In the past 30 days, one estimate has gone higher for BioTelemetry while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 25 cents a share 30 days ago, to 28 cents today, a move of 12%.
Current Year Estimates for BEAT
Meanwhile, BioTelemetry’s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 88 cents per share 30 days ago to $1.05 per share today, an increase of 19.3%.
BioTelemetry, Inc. Price and Consensus
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
See Stocks Now>>